Women’s Health Market Size, Growth, Trends, Report 2023-2032
The global women’s health market was valued at USD 41.39 billion in 2022 and it is predicted to surpass around USD 70.43 billion by 2032 with a CAGR of 5.46% from 2023 to 2032. The women’s health market in the United States was accounted for USD 15.6 billion in 2022.
Key Pointers
Report Scope of the Women’s Health Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 42% |
| Revenue Forecast by 2032 | USD 70.43 billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.46% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | AbbVie, Inc.; Bayer AG; Merck & Co., Inc.; Pfizer, Inc; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc; Apothecus Pharmaceutical Corp.; Blairex Laboratories, Inc.; and Ferring B.V. |
Market growth can be attributed to the increase in the geriatric population of women and introduction of new products for women’s health, such as Relugoliz and Orilissa amongst others. Furthermore, favourable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period.The market exhibited lower than the expected growth during the pandemic. Access to contraception and gynecological testing has declined, raising the rate of unsafe abortions and unwanted pregnancies, especially in developing countries. For instance, according to BMC, in the low- and middle-income countries, there has been around a 10% decline in the use of long- and short-acting reversible contraceptives, about 10% decline in essential services related to pregnancy care. All these factors led to a decline in market growth amid the pandemic. Women are more susceptible to various diseases such as osteoporosis, osteoarthritis, endometriosis, and menstrual health disorders.
Around 73% of postmenopausal women experience hot flashes, fatigue, and sleep disturbances, which increase dependence on medications, impairing the quality of life. With aging and the increasing prevalence of obesity, osteoporosis is anticipated to grow. Some of the major factors leading to hormonal imbalance in women are stress, change in dietary habits, and alcohol consumption, is likely to cause fertility issues in women. Polycystic Ovarian Syndrome (PCOS), ovulation problems, and endometriosis are some of the major causes of infertility. According to WHO, in 2021, globally, around 190 million women of reproductive age were affected by endometriosis.
These factors are anticipated to fuel market growth. According to the United Nations, Department of Social and Economic Affairs, approximately 1.1 billion women needed family planning in 2019, out of which 190 million had unmet contraception needs and about 842 million used modern methods of contraception. Owing to the high unmet need for publicly funded contraceptive services and products, federal & state governments are actively working toward improving family planning services and improving access to modern contraceptives.
For instance, in 2020, Germany’s total multilateral funding for sexual & reproductive and family planning was around USD 121.85 million, an increase of about 65% from 2019. Furthermore, agencies such as USAID run reproductive health & family planning programs in more than 30 countries, including South Africa & other African countries, where there is a high unmet need for contraception. However, there are various complications and adverse effects of prolonged use of contraceptives, which lead to an increase in the adoption of traditional contraceptive methods.
Long-term severe adverse effects of oral contraceptive pills, such as stroke, blood clots, decreased libido, vaginal discharge, and increased risk of breast cancer, may limit usage and lead to banning by regulatory agencies. Such factors could hamper market growth during the forecast period. A few key products in the market are Xgeva, Evista, Prolia, Zometa, Mirena, Reclast/Aclasta, NuvaRing, Minastrin 24 Fe, Forteo, Actonel, Premarin, and Ortho Tri-Cy Lo (28). The market for NuvaRing declined by 3% in 2019 and 73% in 2020 primarily due to the introduction of generics following patient expiry in 2018 in the U.S.
Application Insights
The contraceptives segment held the highest market share of more than 36% of the global revenue in 2022 due to increased awareness about family planning and rapid technological advancements in contraception. In addition, favorable government regulations in countries such as the U.S., coupled with growing awareness about various contraceptive methods, are projected to accelerate contraceptives demand. For instance, the U.S. Federal law mandates that all female-controlled contraceptive methods are covered under insurance without any out-of-pocket costs for patients.
Pills are the most common method of contraception used in developed regions such as the U.S. and Europe, whereas in developing countries intrauterine devices and implants are most commonly used. Endometriosis & uterine fibroids segment is likely to grow at a CAGR of 12.93% during the forecast period. The growth can be attributed to the launch of new products for these conditions. For instance, the approval of Orilissa in 2018 in the U.S., and the approval of Myfembree in the U.S. in May 2021 for the treatment of moderate to severe pain associated with uterine fibroids and heavy menstrual bleeding associated with uterine fibroids respectively is expected to drive market growth.
Age segment Insights
On the basis of age group, the global market has been further bifurcated into 50 years & above and others. The 50 years & above age segment is expected to register the fastest growth rate of 6.75% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe. In addition, with a rise in the geriatric population, diseases, such as postmenopausal osteoporosis are also increasing. All these factors are expected to drive the growth of this segment in the years to come.
The others segment, on the other hand, accounted for the largest market share of 64% in 2022 and is estimated to retain the leading position during the forecast period. Women aged below 50 years are of reproductive age, and women’s health issues associated with this age group are more likely related to fertility, such as hormonal infertility, endometriosis, and polycystic ovary syndrome. According to the World Bank, in 2020, globally, around 64.8% of females were aged between 15 to 49 years, which is about 1.9 billion women out of 3.8 billion total female population. All these aforementioned factors boost the growth of the market.
Regional Insights
North America dominated the overall market in 2022 and accounted for the maximum share of 42% of the global revenue. The region will expand further at a steady growth rate, maintaining its market position over the forecast period. This growth was attributed to the early approval & commercialization of products, favorable reimbursement policies, supportive government regulations, and high awareness about the importance of maintaining good health. For instance, in the financial year 2020-2021, the Government of Canada provided USD 50.47 million for family planning due to which 2.5 million women and couples received contraceptive supplies and services.
Such initiatives and awareness campaigns will contribute to the market growth over the forecast period. Asia Pacific is expected to witness the fastest CAGR from 2023 to 2032 due to factors such as increasing awareness about women’s health and wellbeing, rising geriatric population, and various government initiatives for increasing health awareness. For instance, in July 2017, the Government of India increased its investment in family planning from US$ 2 billion to US$ 3 billion by 2020. In addition, as per the 2021-22 budget, the Australian government will invest USD 353.9 million over the next four years to support women’s health.
Women’s Health Market Segmentations:
By Application
By Age
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Women’s Health Market
5.1. COVID-19 Landscape: Women’s Health Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Women’s Health Market, By Application
8.1. Women’s Health Market, by Application, 2023-2032
8.1.1. Postmenopausal Osteoporosis
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hormonal Infertility
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Endometriosis & Uterine Fibroids
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Contraceptives
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Menopause
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Polycystic Ovary Syndrome (PCOS)
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Women’s Health Market, By February
9.1. Women’s Health Market, by February, 2023-2032
9.1.1. 50 years and above
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Others
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Women’s Health Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.2. Market Revenue and Forecast, by February (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.3.2. Market Revenue and Forecast, by February (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.1.4.2. Market Revenue and Forecast, by February (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.2. Market Revenue and Forecast, by February (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.3.2. Market Revenue and Forecast, by February (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.4.2. Market Revenue and Forecast, by February (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.5.2. Market Revenue and Forecast, by February (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.2.6.2. Market Revenue and Forecast, by February (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.2. Market Revenue and Forecast, by February (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.3.2. Market Revenue and Forecast, by February (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.4.2. Market Revenue and Forecast, by February (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.5.2. Market Revenue and Forecast, by February (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.3.6.2. Market Revenue and Forecast, by February (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.2. Market Revenue and Forecast, by February (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.3.2. Market Revenue and Forecast, by February (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.4.2. Market Revenue and Forecast, by February (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.5.2. Market Revenue and Forecast, by February (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Application (2020-2032)
10.4.6.2. Market Revenue and Forecast, by February (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.2. Market Revenue and Forecast, by February (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.3.2. Market Revenue and Forecast, by February (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Application (2020-2032)
10.5.4.2. Market Revenue and Forecast, by February (2020-2032)
Chapter 11. Company Profiles
11.1. AbbVie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bayer AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merck & Co., Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pfizer, Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Teva Pharmaceutical Industries Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Agile Therapeutics
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Amgen, Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Apothecus Pharmaceutical Corp.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Blairex Laboratories, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. and Ferring B.V.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers